Journal article
Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: A pharmacokinetic study
KT Batty, S Salman, BR Moore, J Benjamin, ST Lee, M Page-Sharp, N Pitus, KF Ilett, I Mueller, FW Hombhanje, P Siba, TME Davis
Antimicrobial Agents and Chemotherapy | Published : 2012
DOI: 10.1128/AAC.06250-11
Abstract
Artemisinin-naphthoquine (ART-NQ) is a coformulated antimalarial therapy marketed as a single-dose treatment in Papua New Guinea and other tropical countries. To build on limited knowledge of the pharmacokinetic properties of the components, especially the tetra-aminoquinoline NQ, we studied ART-NQ disposition in Papua New Guinea children aged 5 to 12 years with uncomplicated malaria, comparing a single dose (15 and 6 mg/kg of body weight) administered with water (group 1; n = 13), a single dose (22 and 9 mg/kg) with milk (group 2) (n = 17), and two daily doses of 22 and 9 mg/kg with water (group 3; n = 16). The plasma NQ concentration was assayed by high-performance liquid chromatography, a..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Funding Acknowledgements
[ "This study was funded by the National Health and Medical Research Council (NHMRC) of Australia (grant 634343). S.T.L. was the recipient of a Cranmore Undergraduate Scholarship through the Faculty of Medicine, Dentistry, and Health Science, University of Western Australia, and T.M.E.D. is supported by an NHMRC Practitioner Fellowship.", "F.W.H. has received research funding from Kunming Pharmaceuticals, the manufacturer of ARCO." ]